Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clene Inc.CLNN · Entity 7166 | Chief Financial Officer | June 11, 2026 | June 15, 2026 |
| Lipocine Inc.LPCN · Entity 7696 | Chief Financial Officer | December 07, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clene Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2036-06-10 | Direct | 15,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F1: This option was granted on June 11, 2026 as an option for 15,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 11, 2026 as an option for 15,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested.
Lipocine Inc.
Report date December 07, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2031-12-07 | Direct | 176,000 |
Reported balance
After 2021-12-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-07 · Grant · Acquired 176,000 · Balance 176,000 F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 18:22 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 15,000 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0001437749-26-020635 · rdgdoc.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: common stock · 15,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2026 as an option for 15,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:16 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 35,000 | $0.00 Strike: $5.42 | $0.00 |
DisclosureSEC source: 0001437749-26-001915 · rdgdoc.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: common stock · 35,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2026 as an option for 35,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.42 per share. The options vest immediately upon grant. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:10 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 10,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001437749-25-030014 · rdgdoc.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: common stock · 10,000 shares Expires 2035-09-24 F1 · derivative.exercise_date: This option was granted on September 25, 2025 as an option for 10,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.05 per share. The options vest in 12 equal monthly installments on the 25th day of each calendar month, beginning October 25, 2025, until such shares are fully vested. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 19:51 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001437749-25-029477 · rdgdoc.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: common stock · 10,000 shares Expires 2035-09-17 F1 · derivative.exercise_date: This option was granted on September 18, 2025 as an option for 10,000 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.32 per share. The options vest immediately upon grant. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:05 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-25-001590 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-02-23 F1 · derivative.exercise_date: This option was granted on February 24, 2025 as an option for 20,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.23 per share. The options vest with respect to the first 25% of such shares on February 24, 2026 and then in 36 equal installments of the balance of the shares of Common Stock on the 24th day of each calendar month thereafter beginning March 24, 2026 until such shares are fully vested. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:11 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001562180-24-006353 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-08-15 F1 · derivative.exercise_date: This option was granted on August 16, 2024 as an option for 10,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $5.15 per share. The options vest with respect to 1/12th of such shares on September 16, 2024 and then an additional 1/12th of such options vest on the 16th day of each calendar month thereafter until such shares are fully vested. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:23 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 600,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004945 · primarydocument.xml · derivative · entry 2 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 600,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:23 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 400,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004945 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 400,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 17:50 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 400,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001562180-23-005630 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: This option was granted on June 29, 2023 as an option for 400,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.90 per share. The options vest with respect to the first 25% of such shares on June 29, 2024 and then in 36 equal installments of the balance of the shares of Common Stock on the last day of each calendar month beginning July 29, 2024 until such shares are fully vested. If Clene Inc. has an NDA accepted by the FDA, 50% of the option shares shall vest on that date. If the FDA approves the accepted NDA, the then remaining unvested option shares shall vest on that date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:14 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 125,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001562180-23-001571 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-17 F1 · derivative.exercise_date: This option was granted on February 17, 2023 as an option for 125,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $1.28 per share. The options vest in full on August 17, 2023. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 22:14 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 300,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-22-007531 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-11-04 F1 · derivative.exercise_date: This option was granted on November 4, 2022 as an option for 300,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $1.11 per share. The options vest with respect to the first 25% of such shares on November 4, 2023 and then in 36 equal installments of the balance of the shares of Common Stock on the 4th day of each calendar month thereafter beginning December 4, 2023 until such shares are fully vested. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:15 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 250,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001562180-22-001004 · primarydocument.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option was granted on February 1, 2022 as an option for 250,000 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $2.96 per share. The options vest with respect to the first 25% of such shares on February 1, 2023 and then in 36 equal installments of the balance of the shares of Common Stock on the last day of each calendar month, beginning February 1, 2023, until such shares are fully vested Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:00 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 176,000 | $1.12 Strike: $1.12 | $197,120.00 |
DisclosureSEC source: 0001493152-21-030817 · ownership.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon Stock | 8,437 | $1.35 | $11,389.95 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,504 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:05 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Options (Right to Buy) · Derivative | 160,000 | $1.37 Strike: $1.37 | $219,200.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-12-15 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 70,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · derivative · entry 5 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,754 Underlying: Common Stock · 70,754 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 70,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 3 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 57,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. F4 · derivative.expiration_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon Stock | 17,250 | $1.57 | $27,023.85 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,062 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $1.54 - $1.60. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| January 28, 2020 Filed Jan 28, 2020 21:26 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 132,000 | $0.46 Strike: $0.46 | $60,456.00 |
DisclosureSEC source: 0001638599-20-000106 · doc4_6488.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 28, 2021, while the remaining 2/3 of the shares subject to the award vest monthly on a prorata basis over the following two years. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 15:42 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 70,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,754 Underlying: Common Stock · 70,754 shares Expires 2029-12-05 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 57,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. F5 · derivative.expiration_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon Stock | 17,250 | $0.41 | $7,075.95 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,812 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Represents the weighted average price of shares sold at a price that ranged from $0.4102 - $0.4106. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to buy) · Derivative | 75,000 | $1.46 Strike: $1.46 | $109,500.00 |
DisclosureSEC source: 0001638599-18-001326 · doc4_5816.xml · derivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-12-04 F3 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 115,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-001326 · doc4_5816.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2028-12-04 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common stock · 9,375 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon stock | 2,813 | $3.47 | $9,773.49 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,562 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 23:50 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $3.52 Strike: $3.52 | $264,000.00 |
DisclosureSEC source: 0001638599-17-001222 · doc4_5123.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:42 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 37,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000131 · doc4_4496.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 15:48 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $3.61 Strike: $3.61 | $180,500.00 |
DisclosureSEC source: 0001638599-16-001674 · doc4_4383.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2016-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.